• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促肾上腺皮质激素释放激素(CRH)及其受体(CRHR1和CRHR2)在人子宫内膜癌中的免疫定位:CRHR1作为一种有效的预后因素。

Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.

作者信息

Sato Naoko, Takagi Kiyoshi, Suzuki Takashi, Miki Yasuhiro, Tanaka Sota, Nagase Satoru, Warita Hitoshi, Fukudo Shin, Sato Fumiko, Sasano Hironobu, Ito Kiyoshi

机构信息

Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Int J Gynecol Cancer. 2014 Nov;24(9):1549-57. doi: 10.1097/IGC.0000000000000269.

DOI:10.1097/IGC.0000000000000269
PMID:25254562
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4215916/
Abstract

OBJECTIVE

Corticotropin-releasing hormone (CRH), a major regulator of the stress response, regulates various biological functions through its interaction with CRH receptors 1 (CRHR1) and 2 (CRHR2). CRH, CRHR1, and CRHR2 have recently been reported in several types of carcinoma, but the significance of these proteins has remained largely unknown in human endometrial carcinoma.

MATERIALS AND METHODS

A total of 87 endometrial carcinoma specimens were obtained from Japanese female patients who underwent surgical treatment, fixed in 10% formalin, and embedded in paraffin wax. Immunohistochemistry for CRH, CRHR1, and CRHR2 was performed, and clinical data were obtained from the medical records.

RESULTS

Immunopositivity of CRH, CRHR1, and CRHR2 in the specimens was 26%, 15%, and 10%, respectively. Univariate analysis revealed that immunohistochemical CRH status was positively associated with CRHR1 and CRHR2 status and that CRHR1 status was significantly associated with the risk of recurrence and poorer clinical outcome, whereas CRHR2 status was marginally associated with better prognosis for overall survival. Multivariate analysis demonstrated CRHR1 status as an independent prognostic factor for both disease-free and overall survival.

CONCLUSIONS

These results suggest that intratumoral CRH-CRHR1 signaling plays an important role in the progression of endometrial carcinoma and that CRHR1 is a potent prognostic factor in patients with this disease.

摘要

目的

促肾上腺皮质激素释放激素(CRH)是应激反应的主要调节因子,通过与促肾上腺皮质激素释放激素受体1(CRHR1)和2(CRHR2)相互作用来调节各种生物学功能。最近在几种类型的癌症中报道了CRH、CRHR1和CRHR2,但这些蛋白在人子宫内膜癌中的意义仍 largely unknown。

材料与方法

从接受手术治疗的日本女性患者中获取了总共87份子宫内膜癌标本,用10%福尔马林固定,石蜡包埋。进行了CRH、CRHR1和CRHR2的免疫组织化学检测,并从病历中获取临床数据。

结果

标本中CRH、CRHR1和CRHR2的免疫阳性率分别为26%、15%和10%。单因素分析显示,免疫组织化学CRH状态与CRHR1和CRHR2状态呈正相关,CRHR1状态与复发风险和较差的临床结局显著相关,而CRHR2状态与总体生存的较好预后呈微弱相关。多因素分析表明,CRHR1状态是无病生存和总体生存的独立预后因素。

结论

这些结果表明肿瘤内CRH-CRHR1信号通路在子宫内膜癌进展中起重要作用,且CRHR1是该疾病患者的一个有力预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2938/4215916/5301424eb3f5/igj-24-1549-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2938/4215916/e1009310bde7/igj-24-1549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2938/4215916/5301424eb3f5/igj-24-1549-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2938/4215916/e1009310bde7/igj-24-1549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2938/4215916/5301424eb3f5/igj-24-1549-g005.jpg

相似文献

1
Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.促肾上腺皮质激素释放激素(CRH)及其受体(CRHR1和CRHR2)在人子宫内膜癌中的免疫定位:CRHR1作为一种有效的预后因素。
Int J Gynecol Cancer. 2014 Nov;24(9):1549-57. doi: 10.1097/IGC.0000000000000269.
2
Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.特异性富含AT序列结合蛋白1在子宫内膜癌中的过表达:一项临床病理研究
Int J Gynecol Cancer. 2015 Jan;25(1):4-11. doi: 10.1097/IGC.0000000000000314.
3
Spinal CRH facilitates the micturition reflex via the CRH2 receptor in rats with normal bladder and bladder outlet obstruction.在膀胱和膀胱出口正常及梗阻的大鼠中,脊髓促肾上腺皮质激素释放激素(CRH)通过CRH2受体促进排尿反射。
Sci Rep. 2025 Jan 29;15(1):3604. doi: 10.1038/s41598-025-87990-w.
4
Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples.预测存在非典型复杂增生的子宫内膜腺癌的共存:子宫内膜样本的免疫组织化学分析。
Int J Gynecol Cancer. 2012 Sep;22(7):1264-72. doi: 10.1097/IGC.0b013e31826302a3.
5
Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.晚期、复发性或转移性子宫内膜癌的化疗:Cochrane协作网的系统评价
Ann Oncol. 2007 Mar;18(3):409-20. doi: 10.1093/annonc/mdl417. Epub 2006 Dec 5.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.Wnt信号通路抑制剂Dickkopf3及分泌型卷曲相关蛋白1和4在子宫内膜样腺癌中的表达模式:一项NRG肿瘤学/妇科肿瘤学组研究
Int J Gynecol Cancer. 2016 Jan;26(1):125-32. doi: 10.1097/IGC.0000000000000563.
8
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.雌激素受体、孕激素受体和 L1 细胞黏附分子表达对基于组织学的子宫内膜癌复发预测模型的增值作用:ENITEC 协作研究。
Int J Gynecol Cancer. 2018 Mar;28(3):514-523. doi: 10.1097/IGC.0000000000001187.
9
Alternative splicing-related factor YT521: an independent prognostic factor in endometrial cancer.剪接相关因子 YT521:子宫内膜癌的一个独立预后因素。
Int J Gynecol Cancer. 2010 May;20(4):492-9. doi: 10.1111/IGC.0b013e3181d66ffe.
10
Laparoscopy versus laparotomy for the management of early stage endometrial cancer.腹腔镜手术与开腹手术治疗早期子宫内膜癌的比较
Cochrane Database Syst Rev. 2012 Sep 12(9):CD006655. doi: 10.1002/14651858.CD006655.pub2.

引用本文的文献

1
Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer.促肾上腺皮质激素释放激素及其受体的表达可能与胰腺癌的生存率相关。
Gastro Hep Adv. 2022 Sep 16;2(1):147-155. doi: 10.1016/j.gastha.2022.09.003. eCollection 2023.
2
The expression and possible role of corticotropin-releasing hormone family peptides and their corresponding receptors in gynaecological malignancies and premalignant conditions: a systematic review.促肾上腺皮质激素释放激素家族肽及其相应受体在妇科恶性肿瘤和癌前病变中的表达及可能作用:一项系统综述
Prz Menopauzalny. 2023 Dec;22(4):227-235. doi: 10.5114/pm.2023.133878. Epub 2023 Dec 21.
3

本文引用的文献

1
Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67.乳腺癌中己糖激酶 II:与低氧诱导因子-1α 和 Ki-67 相关的强预后因子。
Cancer Sci. 2013 Oct;104(10):1380-8. doi: 10.1111/cas.12238. Epub 2013 Aug 21.
2
Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.用于预测子宫内膜样型子宫内膜癌患者淋巴转移的个体化风险评分系统。
Gynecol Oncol. 2013 Oct;131(1):103-8. doi: 10.1016/j.ygyno.2013.06.037. Epub 2013 Jul 9.
3
Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma.
G 蛋白偶联受体家族与免疫图谱的联合特征可为子宫内膜癌提供预后和治疗的生物标志物。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14701-14719. doi: 10.1007/s00432-023-05270-4. Epub 2023 Aug 16.
4
Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.用 antalarmin 拮抗促肾上腺皮质激素释放激素受体 1 可减缓子宫内膜异位症的进展。
PLoS One. 2018 Nov 14;13(11):e0197698. doi: 10.1371/journal.pone.0197698. eCollection 2018.
5
Environmental Manipulations as an Effective Alternative Treatment to Reduce Endometriosis Progression.环境干预作为减少子宫内膜异位症进展的有效替代疗法。
Reprod Sci. 2018 Sep;25(9):1336-1348. doi: 10.1177/1933719117741374. Epub 2017 Nov 14.
6
Association of gene coding variation and resting metabolic rate in a multi-ethnic sample of children and adults.儿童和成人多民族样本中基因编码变异与静息代谢率的关联
BMC Obes. 2017 Apr 5;4:12. doi: 10.1186/s40608-017-0145-5. eCollection 2017.
孕激素受体阴性是早期子宫内膜样腺癌患者复发的独立危险因素。
Gynecol Oncol. 2013 Sep;130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015. Epub 2013 Jun 15.
4
Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.男性乳腺癌肿瘤内雌激素浓度及雌激素诱导基因的表达:与女性乳腺癌的比较。
Horm Cancer. 2013 Feb;4(1):1-11. doi: 10.1007/s12672-012-0126-6. Epub 2012 Oct 18.
5
Cancer treatment and survivorship statistics, 2012.癌症治疗与生存统计,2012 年。
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41. doi: 10.3322/caac.21149. Epub 2012 Jun 14.
6
Corticotropin-releasing hormone enhances the invasiveness and migration of Ishikawa cells, possibly by increasing matrix metalloproteinase-2 and matrix metalloproteinase-9.促肾上腺皮质激素释放激素可能通过增加基质金属蛋白酶-2和基质金属蛋白酶-9来增强 Ishikawa 细胞的侵袭性和迁移能力。
J Int Med Res. 2011;39(6):2067-75. doi: 10.1177/147323001103900602.
7
The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.压力对肿瘤生长的影响:外周 CRF 介导压力的促肿瘤作用。
Mol Cancer. 2010 Sep 27;9:261. doi: 10.1186/1476-4598-9-261.
8
Distinct distribution of corticotropin releasing factor receptors in human breast cancer.人类乳腺癌中促肾上腺皮质素释放因子受体的分布差异。
Neuropeptides. 2010 Oct;44(5):355-61. doi: 10.1016/j.npep.2010.06.005. Epub 2010 Jul 13.
9
The corticotropin releasing factor system in cancer: expression and pathophysiological implications.癌症中的促肾上腺皮质激素释放因子系统:表达与病理生理意义。
Cell Mol Life Sci. 2010 Apr;67(8):1293-306. doi: 10.1007/s00018-010-0265-2. Epub 2010 Feb 9.
10
Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.促肾上腺皮质激素释放因子促进乳腺癌细胞的运动性和侵袭性。
Mol Cancer. 2009 Jun 2;8:30. doi: 10.1186/1476-4598-8-30.